Swizzard welcomes Sandra Sieber as Market Entry & Access Director Switzerland


Swizzard Pharma AG, a solution provider that supports biotech and pharma companies in successfully entering and thriving in the Swiss market, welcomes Sandra Sieber as Market Entry & Access Director Switzerland.
With around 15 years of experience in the pharmaceutical industry, Sandra combines extensive commercial expertise with a deep understanding of the Swiss healthcare landscape. Her expertise spans commercial strategy, marketing, medical and regulatory affairs, with a strong track record in product launches, portfolio management and stakeholder engagement.
During her ten years at Pfizer, Sandra played a key role in successfully launching and establishing biosimilar medicines in Switzerland. She managed portfolios across gastroenterology, rheumatology, dermatology and oncology, with responsibility for commercial performance and budgets. Her experience includes working with key healthcare stakeholders, leading cross-functional initiatives and building long-term partnerships across the Swiss healthcare environment.
Sandra holds a Doctor of Veterinary Medicine degree from the University of Bern and a Master of Advanced Studies in Management, Technology and Economics from the ETH Zurich. With strategic thinking, a hands-on approach and a talent for building lasting relationships, Sandra translates complex challenges into practical solutions for biotech and pharma companies.
About Swizzard
Swizzard Pharma AG supports biotech and pharma companies in successfully entering and thriving in the Swiss market. Committed to bringing innovation to Switzerland, Swizzard helps clients maximize the value of their medical breakthroughs through expert market entry, preparation, commercialization and access strategies. With deep industry expertise, hands-on experience and an extensive network, Swizzard delivers fast, efficient, and tailored solutions. The company is led by CEO Michael Zürcher, a seasoned life sciences executive with a strong track record in the industry.





Comments